In a patient with a fasting C‑peptide within the reference interval but inappropriately low relative to the fasting glucose, what does this indicate and what further evaluation and management steps are recommended?

C-Peptide Normal but Inappropriately Low for Fasting Glucose

This pattern indicates impaired insulin secretory capacity and suggests evolving beta-cell dysfunction, most commonly seen in early type 1 diabetes (including latent autoimmune diabetes in adults), monogenic diabetes, or advanced type 2 diabetes with significant beta-cell failure. The key issue is that while the absolute C-peptide value falls within the laboratory reference range, it is inadequate relative to the degree of hyperglycemia present—a healthy pancreas would produce substantially more insulin (and thus C-peptide) in response to elevated glucose.

Understanding the Clinical Significance

The C-peptide-to-glucose ratio (CGR) provides a more meaningful assessment than absolute C-peptide values alone 1. When fasting C-peptide appears "normal" but glucose is elevated, the pancreas is failing to appropriately compensate for hyperglycemia. This represents relative insulin deficiency rather than absolute deficiency, but signals progressive beta-cell failure.

Research demonstrates that even low-normal C-peptide levels (<50-100 pmol/L or <0.3-0.6 ng/mL) have clinical significance, being associated with:

• Higher risk of diabetic complications 2
• Poorer glycemic control 2, 3
• Increased hypoglycemia risk 4, 2
• Greater glucose variability 3

Immediate Evaluation Steps

1. Measure Islet Autoantibodies

Test for GAD antibodies first, followed by IA-2 and ZnT8 if GAD is negative 5. This distinguishes autoimmune diabetes (type 1 or LADA) from other causes. Notably, 5-10% of adult-onset type 1 diabetes patients are antibody-negative, so negative results don't exclude autoimmune etiology 5.

2. Assess for Monogenic Diabetes Features

Look for specific indicators 5:

• A1C <7.5% at diagnosis despite hyperglycemia
• Parent with diabetes (autosomal dominant inheritance pattern)
• Renal cysts, partial lipodystrophy, or maternally inherited deafness
• Young age at diagnosis with preserved C-peptide
• Use the MODY probability calculator if appropriate (diabetesgenes.org)

3. Evaluate Clinical Context

• Age at diagnosis: <35 years favors type 1 diabetes 5
• BMI and weight trajectory: Low BMI or weight loss suggests insulin deficiency 5
• Ketosis history: Presence of ketoacidosis strongly indicates insulin deficiency 5
• Duration of diabetes: If >3 years with persistent C-peptide 200-600 pmol/L, consider type 2 or monogenic diabetes 5, 6

Management Algorithm

Step 1: Determine Insulin Requirement

• If C-peptide <200 pmol/L (<0.6 ng/mL): This indicates significant insulin deficiency requiring insulin therapy 5. Even if within the reference range, this level is inadequate for the degree of hyperglycemia.
• If C-peptide 200-600 pmol/L (0.6-1.8 ng/mL): This intermediate range typically indicates type 1 diabetes or MODY but requires clinical correlation 5. Insulin therapy is usually necessary.
• If C-peptide >600 pmol/L (>1.8 ng/mL): Type 2 diabetes is more likely, though this scenario contradicts your question premise 5.

Step 2: Initiate or Modify Therapy

For insulin-deficient phenotypes (low-normal C-peptide with hyperglycemia):

• Start basal insulin immediately if not already on insulin 7
• Use lower initial doses than typical for type 2 diabetes—these patients are insulin-sensitive despite hyperglycemia 4
• Titrate cautiously to avoid hypoglycemia 4
• Avoid or discontinue SGLT2 inhibitors due to diabetic ketoacidosis risk in insulin-deficient states 7
• Consider early addition of prandial insulin rather than escalating basal doses 4

Step 3: Ongoing Monitoring

• Repeat C-peptide testing after 3-5 years if diagnosis remains unclear 5, 6
• Monitor for hypoglycemia more intensively—lower C-peptide predicts higher hypoglycemia risk 4, 2
• Assess for complications more frequently, as even low-normal C-peptide associates with increased complication rates 2

Critical Pitfalls to Avoid

1. Don't rely solely on reference ranges: A C-peptide of 0.8 ng/mL might be "normal" but is grossly inadequate if fasting glucose is 250 mg/dL 1.

2. Don't assume type 2 diabetes based on age or BMI alone: Autoimmune diabetes occurs at any age, and obesity doesn't exclude type 1 diabetes 7.

3. Don't prescribe SGLT2 inhibitors without confirming adequate insulin reserve: This can precipitate euglycemic DKA in insulin-deficient patients 7.

4. Don't delay insulin therapy: Attempting non-insulin agents in insulin-deficient patients leads to poor outcomes and potential ketoacidosis 7.

5. Timing matters for C-peptide measurement: Avoid testing within 2 weeks of hyperglycemic emergency, and ensure concurrent glucose is documented 5, 8. If glucose <70 mg/dL at time of testing, results may be falsely low and should be repeated 5.

When Genetic Testing is Indicated

If C-peptide is >200 pmol/L and monogenic diabetes features are present, pursue genetic testing where available 5. Confirming MODY can fundamentally change management, potentially allowing sulfonylurea monotherapy instead of insulin in certain subtypes.

The bottom line: Normal-range C-peptide that is inappropriately low for the degree of hyperglycemia signals progressive beta-cell failure requiring insulin therapy, autoantibody testing to determine etiology, and heightened vigilance for hypoglycemia and complications 5, 7, 4, 2.